High-Tech Gruenderfonds and Life Science Fonds Esslingen invest in Amedrix GmbH
In the body of the patient the implants are populated by his own cells which proliferate and assimilate their specific synthesis activity. Compared with the already available cellsettled products on the market it has the benefit that additional and expensive operations for cell withdrawal and long waiting periods for the patients are not necessary. Amedrix GmbH has set up the technology on the collagen and implant production and has tested the first prototypes for functionality and biocompatibility. The market launch of the first products is expected for the year 2010.
It is planned to distribute the products through partners already established in the market. "Key success factors of new products are the enhanced treatment options", says Dr. Thomas Graeve, founder and managing director of Amedrix GmbH. "The quality of the patient's care improves with the quality of the products and the areas of application. Minimalinvasive procedures are good examples for such methods." Through the application of medical devices for the regenerative medicine costs can be lowered significantly for health insurance companies. "Because this applies in particular to subsequent costs arising from especially complex treatments, we assume a high acceptance ", according to Dr. Thomas Graeve.
The new funds enable the company to undertake the necessary steps to get approval for the first products and to build up its own production. With a broad spectrum of different medical implants Dr. Graeve aims to build up and develop a stable business in the region.
Dr. Michael Nettersheim, Investment Manager at High-Tech Gruenderfonds Management GmbH comments: "Amedrix' close to market medical devices exactly meet the current market demand. By reducing the number of surgical interventions Amedrix' products are substantially cheaper and provide a much higher patient convenience compared to alternative products."
Stephan Reichstein, manager of the Life Science Fonds Esslingen, adds: " As a local business developer we do not only offer lab and office space but also provide funding for the development of promising company like Amedrix. An investment in the company is an investment intom our region - the city of engineering, Esslingen."
About LSF Esslingen:
The Life Science Fonds Esslingen GmbH & Co. KG was founded jointly by the city of Esslingen am Neckar, the business development of the city of Esslingen, Kreissparkasse Esslingen-Nuertingen, Volksbank Esslingen as well as private investors as own venture capital fund.
Therefore the city of Esslingen is able to offer not only rooms for laboratories and offices, but also venture capital. This is administered by the Life Science Fonds Esslingen Verwaltungs-GmbH. In particular the young biotechnology companies located in the Life Science Center Esslingen profits from this support.
High-Tech Gründerfonds Management GmbH
The High-Tech Gruenderfonds invests venture capital in young, innovative technology companies, which implement promising research results corporate. With the help of the seed financing from up to 500,000 EUR the startup companies should lead their R&D projects up to the appropriation of a prototype and "proof of concepts" respectively or to the market launch. The High-Tech Gruenderfonds has a fund volume of about 272m EUR. Investors of the publicprivate partnership are the Federal Ministry for Economics and Technology, the KfW bank group as well as the six industrial groups BASF, Deutsche Telekom, Siemens, Robert Bosch, Daimler and Carl Zeiss.